Results 1 to 10 of about 64,945 (43)

Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. [PDF]

, 2014
Preclinical studies demonstrate that epidermal growth factor receptor (EGFR) signals through both kinase-dependent and independent pathways and that combining a small-molecule EGFR inhibitor, EGFR antibody, and/or anti-angiogenic agent is synergistic. We
Bastida, Christel, Falchook, Gerald S, Fu, Siqing, Hess, Kenneth R, Hong, David S, Janku, Filip, Kurzrock, Razelle, Naing, Aung, Piha-Paul, Sarina A, Tsimberidou, Apostolia M, Wheler, Jennifer J, Zinner, Ralph   +11 more
core   +10 more sources

Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy. [PDF]

, 2017
Anti-angiogenic therapies for cancer such as VEGF neutralizing antibody bevacizumab have limited durability. While mechanisms of resistance remain undefined, it is likely that acquired resistance to anti-angiogenic therapy will involve alterations of the
Aghi, MK, Castro, BA, Chen, W, De Lay, M, Flanigan, P, Hoffman, D, Jahangiri, A, Kohanbash, G, Kuang, R, Mascharak, S, Okada, H, Shrivastav, S, Sidorov, M, Wagner, JR, Yagnik, G   +14 more
core   +1 more source

Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer [PDF]

, 2010
Objectives: Bevacizumab is a monoclonal antibody that directly inhibits vascular endothelial growth factor, a key regulator of angiogenesis. Bevacizumab significantly improves progression-free and/or overall survival in metastatic colorectal cancer in ...
Heinemann, Volker, Hoff, Paulo M.
core   +1 more source

Who Is In Charge, and Who Should Be? The Disciplinary Role of the Commander in Military Justice Systems [PDF]

, 2006
BackgroundStandard therapy for newly diagnosed glioblastoma is radiotherapy plus temozolomide. In this phase 3 study, we evaluated the effect of the addition of bevacizumab to radiotherapy-temozolomide for the treatment of newly diagnosed glioblastoma ...
Abrey, Lauren, Brandes, Alba A., Carpentier, Antoine F., Cernea, Dana, Chinot, Olivier L., Cloughesy, Timothy, Henriksson, Roger, Hilton, Magalie, Hoang-Xuan, Khe, Kavan, Petr, Mason, Warren, Nishikawa, Ryo, Saran, Frank, Wick, Wolfgang   +13 more
core   +3 more sources

The addition of bevacizumab to standard chemotherapy in breast cancer : which patient benefits the most? [PDF]

, 2013
Bevacizumab, a humanized monoclonal antibody directed against vascular endothelial growth factor, is an effective and well-tolerated treatment option for patients with breast cancer.
Cocquyt, Veronique, Denys, Hannelore, KRUSE, VIBEKE, Van Belle, Simon, Van den Broecke, Rudy   +4 more
core   +2 more sources

Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. [PDF]

, 2018
BackgroundWe performed a phase I modified 3 + 3 dose escalation study to evaluate the safety and activity of bevacizumab plus gemcitabine and nab-paclitaxel in patients with advanced solid tumours.MethodsPatients were given fixed dose gemcitabine plus ...
Agarwal, Rishi, Bass, Allison, Bean, Stacie, Byers, Lauren, Falchook, Gerald, Fu, Siqing, Hess, Kenneth, Hong, David, Janku, Filip, Karp, Daniel, Kato, Shumei, Kurzrock, Razelle, Lim, JoAnn, Meric-Bernstam, Funda, Naing, Aung, Nguyen, Ly, Pant, Shubham, Piha-Paul, Sarina, Sen, Shiraj, Subbiah, Vivek, Tang, Chad, Tsimberidou, Apostolia, Westin, Shannon, Wu, Xifeng, Ye, Yuanqing   +24 more
core   +2 more sources

Salvage Fractionated Stereotactic Re-irradiation (FSRT) for Patients with Recurrent High Grade Gliomas Progressed after Bevacizumab Treatment [PDF]

, 2017
Purpose/Objectives: Bevacizumab failure is a major clinical problem in the manage- ment of high grade gliomas (HGG), with a median overall survival of less than 4 months (m).
Andrews MD, David W., Bar-Ad, Voichita, Bhamidipati, Deepak, Blomain, Erik S, Dan, Tu, Evans, James J., Farrell, MD, Christopher J, Glass, MD, Jon, Judy, MD, Kevin, Kim, Lyndon, Palmer, Joshua, Shi, Wenyin, Siglin, Joshua, Wang, Yang, Werner-Wasik, Maria   +14 more
core   +2 more sources

Repeating platinum/bevacizumab in recurrent or progressive cervical cancer yields marginal survival benefits [PDF]

, 2017
Our objective was to assess overall survival of cervical cancer patients following prior platinum/bevacizumab chemotherapy, comparing retreatment with platinum/bevacizumab with alternative therapies.
Massad, L. Stewart, Powell, Matthew A, Wan, Leping, Zamorano, Abigail S   +3 more
core   +3 more sources

Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials [PDF]

, 2015
Background: To analyze the efficacy and toxicity of bevacizumab on survival outcomes in recurrent ovarian cancer. Results: Bevacizumab was associated with significant improvement of PFS and OS compared with standard treatment with HRs of 0.53 (95% CI 0.
BENEDETTI PANICI, PIERLUIGI, DE FELICE, FRANCESCA, DI DONATO, VIOLANTE, GASPARRI, MARIALUISA, Marchetti, C, MUSELLA, ANGELA, Musio, D, MUZII, LUDOVICO, PALAIA, INNOCENZA, TOMBOLINI, Vincenzo   +9 more
core   +1 more source

Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia [PDF]

, 2007
Background: Irinotecan-based second-line chemotherapy of metastatic colorectal cancer (CRC) is effective, it might, however, be contraindicated in cases of severe liver dysfunction due to advanced liver metastases.
Heinemann, Volker, Laessig, Dorit, Michaely, Henrik Jakob, Moosmann, Nicolas, Schulz, Christoph   +4 more
core   +1 more source